Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Long-Term Investments: 2010-2016

Historic Long-Term Investments for Northwest Biotherapeutics (NWBO) over the last 3 years, with Jun 2016 value amounting to $77,000.

  • Northwest Biotherapeutics' Long-Term Investments fell 89.58% to $77,000 in Q2 2016 from the same period last year, while for Jun 2016 it was $77,000, marking a year-over-year decrease of 89.58%. This contributed to the annual value of $349,000 for FY2015, which is 80.17% down from last year.
  • Northwest Biotherapeutics' Long-Term Investments amounted to $77,000 in Q2 2016, which was down 64.02% from $214,000 recorded in Q1 2016.
  • Over the past 5 years, Northwest Biotherapeutics' Long-Term Investments peaked at $1.8 million during Q4 2014, and registered a low of $17,000 during Q4 2012.
  • Moreover, its 3-year median value for Long-Term Investments was $418,500 (2015), whereas its average is $625,000.
  • Its Long-Term Investments has fluctuated over the past 5 years, first skyrocketed by 2,296.36% in 2015, then tumbled by 89.58% in 2016.
  • Over the past 5 years, Northwest Biotherapeutics' Long-Term Investments (Quarterly) stood at $17,000 in 2012, then plummeted by 48.48% to $17,000 in 2013, then surged by 223.53% to $1.8 million in 2014, then crashed by 80.17% to $349,000 in 2015, then plummeted by 89.58% to $77,000 in 2016.
  • Its Long-Term Investments stands at $77,000 for Q2 2016, versus $214,000 for Q1 2016 and $349,000 for Q4 2015.